These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 33756123)
1. Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria. Halloy F; Iyer PS; Ghidini A; Lysenko V; Barman-Aksözen J; Grubenmann CP; Jucker J; Wildner-Verhey van Wijk N; Ruepp MD; Minder EI; Minder AE; Schneider-Yin X; Theocharides APA; Schümperli D; Hall J Cell Chem Biol; 2021 Aug; 28(8):1221-1234.e6. PubMed ID: 33756123 [TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-Mediated Wijerathna HMSM; Shanaka KASN; Raguvaran SS; Jayamali BPMV; Kim SH; Kim MJ; Jung S; Lee J Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39409147 [TBL] [Abstract][Full Text] [Related]
3. Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria. Delaby C; Lyoumi S; Ducamp S; Martin-Schmitt C; Gouya L; Deybach JC; Beaumont C; Puy H Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):45-52. PubMed ID: 19268001 [TBL] [Abstract][Full Text] [Related]
4. In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability. Barman-Aksözen J; Minder EI; Schubiger C; Biolcati G; Schneider-Yin X Blood Cells Mol Dis; 2015 Jan; 54(1):71-7. PubMed ID: 25179834 [TBL] [Abstract][Full Text] [Related]
5. Liver metabolomics in a mouse model of erythropoietic protoporphyria. Wang P; Sachar M; Guo GL; Shehu AI; Lu J; Zhong XB; Ma X Biochem Pharmacol; 2018 Aug; 154():474-481. PubMed ID: 29906468 [TBL] [Abstract][Full Text] [Related]
6. The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria. Wang P; Sachar M; Lu J; Shehu AI; Zhu J; Chen J; Liu K; Anderson KE; Xie W; Gonzalez FJ; Klaassen CD; Ma X Sci Adv; 2019 Sep; 5(9):eaaw6127. PubMed ID: 31555729 [TBL] [Abstract][Full Text] [Related]
7. Distribution of protoporphyrin IX in erythrocytes in a case of acquired erythropoietic protoporphyria. Heerfordt IM; Fontenete S; Lerche CM; Wulf HC Photodiagnosis Photodyn Ther; 2022 Mar; 37():102629. PubMed ID: 34798346 [TBL] [Abstract][Full Text] [Related]
8. Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity. Barman-Aksoezen J; Girelli D; Aurizi C; Schneider-Yin X; Campostrini N; Barbieri L; Minder EI; Biolcati G J Inherit Metab Dis; 2017 May; 40(3):433-441. PubMed ID: 28185024 [TBL] [Abstract][Full Text] [Related]
9. Delta-aminolevulinic acid synthase 2 expression in combination with iron as modifiers of disease severity in erythropoietic protoporphyria. Barman-Aksözen J; Halloy F; Iyer PS; Schümperli D; Minder AE; Hall J; Minder EI; Schneider-Yin X Mol Genet Metab; 2019 Nov; 128(3):304-308. PubMed ID: 31076252 [TBL] [Abstract][Full Text] [Related]
10. Light-provoked skin symptoms on the hands of erythropoietic protoporphyria patients related to personal dosimeter measurements, skin symptoms, light protection and priming. Heerfordt IM; Heydenreich J; Philipsen PA; Lerche CM; Wulf HC J Photochem Photobiol B; 2020 Dec; 213():112054. PubMed ID: 33075648 [TBL] [Abstract][Full Text] [Related]
11. Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice. Barman-Aksözen J; C Wiek P; Bansode VB; Koentgen F; Trüb J; Pelczar P; Cinelli P; Schneider-Yin X; Schümperli D; Minder EI Dis Model Mech; 2017 Mar; 10(3):225-233. PubMed ID: 28093505 [TBL] [Abstract][Full Text] [Related]
12. Erythroid-Progenitor-Targeted Gene Therapy Using Bifunctional TFR1 Ligand-Peptides in Human Erythropoietic Protoporphyria. Mirmiran A; Schmitt C; Lefebvre T; Manceau H; Daher R; Oustric V; Poli A; Lacapère JJ; Moulouel B; Puy H; Karim Z; Peoc'h K; Lenglet H; Simonin S; Deybach JC; Nicolas G; Gouya L Am J Hum Genet; 2019 Feb; 104(2):341-347. PubMed ID: 30712775 [TBL] [Abstract][Full Text] [Related]
13. Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics. Hussain Z; Qi Q; Zhu J; Anderson KE; Ma X Pharmacol Ther; 2023 Aug; 248():108487. PubMed ID: 37392940 [TBL] [Abstract][Full Text] [Related]
14. Inactivation of protoporphyrin IX in erythrocytes in patients with erythropoietic protoporphyria: A new treatment modality. Wulf HC; Nissen CV; Philipsen PA Photodiagnosis Photodyn Ther; 2020 Mar; 29():101582. PubMed ID: 31809913 [TBL] [Abstract][Full Text] [Related]
15. Neonatal bone marrow transplantation prevents liver disease in a murine model of erythropoietic protoporphyria. Duchartre Y; Petit N; Moya C; Lalanne M; Dubus P; Verneuil Hd; Moreau-Gaudry F; Richard E J Hepatol; 2011 Jul; 55(1):162-70. PubMed ID: 21145811 [TBL] [Abstract][Full Text] [Related]
16. Biochemical abnormality in erythropoietic protoporphyria: cause and consequences. Bloomer JR; Wang Y; Singhal A; Risheg H J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S36-40. PubMed ID: 16819399 [TBL] [Abstract][Full Text] [Related]
18. Trends in erythrocyte protoporphyrin IX concentration by age, sex and season among patients with erythropoietic protoporphyria-20 years of follow-up. Heerfordt IM; Lerche CM; Wulf HC Photodiagnosis Photodyn Ther; 2020 Dec; 32():101928. PubMed ID: 32717453 [TBL] [Abstract][Full Text] [Related]
19. Recognized and Emerging Features of Erythropoietic and X-Linked Protoporphyria. Di Pierro E; Granata F; De Canio M; Rossi M; Ricci A; Marcacci M; De Luca G; Sarno L; Barbieri L; Ventura P; Graziadei G Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054318 [TBL] [Abstract][Full Text] [Related]
20. Effects of iron supplements in individuals with erythropoietic protoporphyria. Heerfordt IM; Lerche CM; Philipsen PA; Wulf HC Photodiagnosis Photodyn Ther; 2024 Jun; 47():104211. PubMed ID: 38734198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]